The Ion Smart and Resilient Cities Accelerator has announced its most recent cohort ahead of moving into the physical hub later this year. Photo by Natalie Harms/InnovationMap

The Ion Smart and Resilient Cities Accelerator has named the five companies participating in its latest cohort, which starts next week.

Launched in 2019, the programing for the accelerator and its member companies focus on addressing the needs and challenges the city of Houston and other major metros are facing — including climate change. The five selected companies will start the 12-week program next week with a goal of securing a pilot with the city.

"We're thrilled to kick-off Cohort 3," says Christine Galib, senior director of programs at The Ion, in a news release. "The ISRCA remains a core asset in The Ion's Programs portfolio, since it enables recurring collisions, connections, and collaborations among startups, stakeholders, and subject-matter experts."

The selected startups are:

  • Phase Filter/Kinetic Synergies: The university-born startup has created an automatically changing air filter that works with existing HVAC systems to lower cost and energy use as well as eliminate the annoying chore.
  • Frakktal: In an effort to create a circular economy, Frakktal repurposes and reuses discarded polymer materials from the greater Gulf Coast region to also use in the same region.
  • Moonshot Compost: The company collects food waste from Houston residents and businesses via curbside pickup and drop-off while also collects and provides data on each pickup.
  • Teratonix: Using radio frequency (RF) electromagnetic from radio /TV broadcast, cell phone tower, wifi routers, and more, Teratonix provides solutions to generate electricity.
  • Smart Watts:The company taps into smart meter sensors to enable a personalized energy monitoring dashboard that provides users with data to make better energy use decisions.

"The ISRCA Cohort 3 will highlight companies that focus on making sure Houston is here for generations to come," says Courtney Cogdill, program manager for The Accelerator Hub at The Ion, in the release. "By activating the Houston innovation ecosystem and showcasing Houston's talent, Cohort 3 will spotlight Houston as a city committed to sustainability."

The previous cohorts of the program focused on resilience and mobility in Cohort 1 and cleantech for Cohort 2.

"As the world-at-large expands their mobility with social distancing restrictions lifted, it's important cities and businesses review their sustainability practices and carbon footprint and continue to improve upon the progress that's been made," says Jan E. Odegard, interim executive director of The Ion, in the release. "The Ion is excited to empower entrepreneurs who will play a critical role in improving sustainability. With Houston and our diverse and innovative industries as a backdrop, The Ion is prepared to address the challenges sustainability will face in a post COVID-19 world."

The program will be housed in The Ion, a 266,000-square-foot mixed-use structure, which is expected to open within the next few months, along with the organization's other accelerator programs.

Learn more about The Ion's accelerators by streaming this recent Houston Innovators Podcast with Galib and Cogdill:

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”